Canada Markets close in 2 hrs 42 mins

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1800-0.0100 (-0.46%)
As of 01:03PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.1900
Open2.2600
Bid2.1800 x 1000
Ask2.1900 x 1000
Day's Range2.1800 - 2.2600
52 Week Range1.7600 - 2.7000
Volume5,036
Avg. Volume39,786
Market Cap31.414M
Beta (5Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-2.0670
Earnings DateMar 13, 2023 - Mar 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    James Flynn Joins ARCA biopharma Board of Directors

    WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium

  • Simply Wall St.

    One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year

    Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...

  • GlobeNewswire

    ARCA biopharma Announces Third Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retaine